Mount Yale Investment Advisors LLC Purchases 137 Shares of Zoetis Inc. (NYSE:ZTS)

Mount Yale Investment Advisors LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 3.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,503 shares of the company’s stock after acquiring an additional 137 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in Zoetis were worth $880,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ZTS. Webster Bank N. A. lifted its stake in Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares during the last quarter. Quarry LP lifted its stake in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after acquiring an additional 153 shares during the last quarter. LRI Investments LLC bought a new stake in shares of Zoetis during the 1st quarter worth approximately $43,000. Central Valley Advisors LLC purchased a new position in Zoetis during the 2nd quarter valued at $49,000. Finally, EdgeRock Capital LLC bought a new position in Zoetis in the 2nd quarter valued at $56,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $180.01 on Friday. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $82.14 billion, a price-to-earnings ratio of 34.68, a price-to-earnings-growth ratio of 2.94 and a beta of 0.89. The firm has a 50 day moving average of $189.18 and a 200 day moving average of $177.61. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same period in the prior year, the business posted $1.41 EPS. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. On average, sell-side analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.96%. Zoetis’s payout ratio is 33.14%.

Analysts Set New Price Targets

ZTS has been the subject of several research analyst reports. Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Stifel Nicolaus lifted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. upped their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. BTIG Research lifted their price target on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.